Management of type 2 diabetes after metabolic bariatric surgery

Abstract

Metabolic and bariatric surgery has been proven to be effective in the glycemic and metabolic control of type 2 diabetes (T2D) and obesity. While most patients experience remission of T2D after surgery, some individuals remain with suboptimal glycemic control. In addition, a significant subset of patients experience relapse of diabetes in the long term after attaining diabetes remission. As a heterogenous disease, the underlying etiology of T2D and response to treatment can be variable in different individuals. The mechanism of diabetes relapse is not completely understood as is the optimal medical management of T2D after metabolic and bariatric surgery. Nonetheless, person-centred collaborative and supportive care beyond the monitoring of parameters forms the cornerstone in formulating care for people with diabetes. This paper reviews the clinical management of T2D after bariatric surgery, including persistent T2D or diabetes relapse after initial remission.

Keywords

Metabolic bariatric surgery / remission and relapse / pharmacotherapy / outcomes

References

[1] Cummings DE.Metabolic surgery for the treatment of type 2 diabetes in obese individuals.Diabetologia2018;61:257-64 PMCID:PMC6448954

[2] Rubino F,Eckel RH.Delegates of the 2nd Diabetes Surgery SummitMetabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations.Diabetes Care2016;39:861-77

[3] Tham KW,Cua SC.Obesity in South and Southeast Asia - A new consensus on care and management.Obes Rev2023;24:e13520 PMCID:PMC10078503

[4] ElSayed NA,Aroda VR.8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes - 2023.Diabetes Care2023;46:S128-39 PMCID:PMC9810466

[5] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.Diabetologia2016;59:1121-40

[6] Gloy VL,Bhatt DL.Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.BMJ2013;347:f5934 PMCID:PMC3806364

[7] Schauer PR,Ikramuddin S.Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes.Diabetes Care2016;39:902-11 PMCID:PMC5864131

[8] Buchwald H,Fahrbach K.Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.Am J Med2009;122:248-56.e5

[9] Mingrone G,De Gaetano A.Bariatric surgery versus conventional medical therapy for type 2 diabetes.N Engl J Med2012;366:1577-85

[10] Dixon JB,Playfair J.Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.JAMA2008;299:316-23

[11] Courcoulas AP,Neiberg RH.Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial.J Clin Endocrinol Metab2020;105:866-76 PMCID:PMC7032894

[12] Sjöström L,Peltonen M.Swedish Obese Subjects Study Scientific GroupLifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.N Engl J Med2004;351:2683-93

[13] Mingrone G,De Gaetano A.Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.Lancet2021;397:293-304

[14] Arterburn DE,Sherwood NE.A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass.Obes Surg2013;23:93-102 PMCID:PMC4641311

[15] Riddle MC,Evans PH.Consensus report: definition and interpretation of remission in type 2 diabetes.Diabetes Care2021;44:2438-44 PMCID:PMC8929179

[16] DeFronzo RA.Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.Diabetes2009;58:773-95 PMCID:PMC2661582

[17] Taylor R.Type 2 diabetes: etiology and reversibility.Diabetes Care2013;36:1047-55

[18] Skyler JS,Bonifacio E.Differentiation of diabetes by pathophysiology, natural history, and prognosis.Diabetes2017;66:241-55 PMCID:PMC5384660

[19] Khoo CM,Taslim S.Ethnicity modifies the relationships of insulin resistance, inflammation, and adiponectin with obesity in a multiethnic Asian population.Diabetes Care2011;34:1120-6 PMCID:PMC3114514

[20] Caleyachetty R,Mohammed NI.Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study.Lancet Diabetes Endocrinol2021;9:419-26 PMCID:PMC8208895

[21] Yabe D,Fukushima M.β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians.Curr Diab Rep2015;15:602 PMCID:PMC4420838

[22] Tabák AG,Akbaraly TN,Kivimäki M.Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.Lancet2009;373:2215-21 PMCID:PMC2726723

[23] Matthews DR,Stratton IM,Turner RC.UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years.Diabet Med1998;15:297-303

[24] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet1998;352:837-53

[25] Steven S,Small PK.Reversal of type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes.Diabet Med2015;32:47-53

[26] Wesolowska-Andersen A,Bizzotto R.IMI DIRECT ConsortiumFour groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study.Cell Rep Med2022;3:100477 PMCID:PMC8784706

[27] Steven S,Al-Mrabeh A.Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders.Diabetes Care2016;39:808-15

[28] Taylor R,Zhyzhneuskaya S.Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery.Cell Metab2018;28:547-56.e3

[29] Panunzi S,De Gaetano A.Determinants of diabetes remission and glycemic control after bariatric surgery.Diabetes Care2016;39:166-74

[30] Pessoa BM,Mazzini GS.Factors mediating type 2 diabetes remission and relapse after gastric bypass surgery.J Am Coll Surg2020;230:7-16

[31] Dutia R,Bunker P.Response to comment on Dutia et al. Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission. Diabetes 2014;63:1214−1223.Diabetes2014;63:e4 PMCID:PMC4179312

[32] Schauer PR,Kirwan JP.STAMPEDE InvestigatorsBariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes.N Engl J Med2017;376:641-51 PMCID:PMC5451258

[33] Aminian A,Andalib A.Individualized metabolic surgery score: procedure selection based on diabetes severity.Ann Surg2017;266:650-7

[34] Lim EL,Aribisala BS,Mathers JC.Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.Diabetologia2011;54:2506-14 PMCID:PMC3168743

[35] Chumakova-Orin M,Moris DP.Diabetes remission after bariatric surgery.World J Diabetes2021;12:1093-101 PMCID:PMC8311476

[36] Watanabe Y,Nagayama D.Factors associated with relapse of type 2 diabetes mellitus after laparoscopic sleeve gastrectomy in Japanese subjects: a subgroup analysis of J-SMART study.Obes Facts2023;16:119-30 PMCID:PMC10028371

[37] Jans A,Näslund I,Näslund E.Factors affecting relapse of type 2 diabetes after bariatric surgery in Sweden 2007-2015: a registry-based cohort study.Surg Obes Relat Dis2022;18:305-12

[38] Aminian A,Salminen P.Late relapse of diabetes after bariatric surgery: not rare, but not a failure.Diabetes Care2020;43:534-40

[39] Debédat J,Coupaye M.Long-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance.Diabetes Care2018;41:2086-95

[40] Inge TH, Courcoulas AP, Jenkins TM, et al; Teen-LABS Consortium. Five-year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med 2019;380:2136-45.

[41] Lee PC,Ganguly S,Eng AKH.Ethnicity does not influence glycemic outcomes or diabetes remission after sleeve gastrectomy or gastric bypass in a multiethnic Asian cohort.Obes Surg2018;28:1511-8

[42] Chen X.Diabetes remission and relapse after metabolic surgery.J Diabetes Investig2018;9:1237-8 PMCID:PMC6215947

[43] ElSayed NA,Aroda VR.Addendum. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes - 2023. Diabetes Care 2023;46 (Suppl. 1):S49-S67.Diabetes Care2023;46:1718-20

[44] Rodriguez K,Dickinson JK.Improving quality outcomes: the value of diabetes care and education specialists.Clin Diabetes2022;40:356-65 PMCID:PMC9331628

[45] Gaede P,Parving HH.Effect of a multifactorial intervention on mortality in type 2 diabetes.N Engl J Med2008;358:580-91

[46] Gæde P,Carstensen B.Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.Diabetologia2016;59:2298-307 PMCID:PMC5506099

[47] Samson SL,Blonde L.American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm - 2023 update.Endocr Pract2023;29:305-40

[48] Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

[49] Mechanick JI,Brethauer S.Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists.Endocr Pract2019;25:1346-59

[50] Dicker D,Comaneshter DS.Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission.Obes Surg2016;26:1814-20

[51] Aminian A,Burguera B.Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery.Diabetes Care2016;39:e50-3 PMCID:PMC8176207

[52] Kheniser KG.Diabetes management before, during, and after bariatric and metabolic surgery.J Diabetes Complications2018;32:870-5

[53] Rometo D.Perioperative glycemic management of patients undergoing bariatric surgery.Curr Diab Rep2016;16:23

[54] Busetto L,Azran C.Practical recommendations of the obesity management task force of the European Association for the study of obesity for the post-bariatric surgery medical management.Obes Facts2017;10:597-632 PMCID:PMC5836195

[55] le Roux CW,Batterham RL.Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.Ann Surg2006;243:108-14 PMCID:PMC1449984

[56] Dirksen C,Bojsen-Møller KN.Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass.Int J Obes2013;37:1452-9

[57] Nannipieri M,Mari A.Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones.J Clin Endocrinol Metab2013;98:4391-9

[58] Miras AD,Aldhwayan M.Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol2019;7:549-59

[59] Htike ZZ,Papamargaritis D,Khunti K.Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis.Diabetes Obes Metab2017;19:524-36

[60] Tan T,Tharakan G.The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers.J Clin Endocrinol Metab2017;102:2364-72 PMCID:PMC5505203

[61] Marso SP,Consoli A.SUSTAIN-6 InvestigatorsSemaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med2016;375:1834-44

[62] Wilding JPH,Calanna S.STEP 1 Study GroupOnce-weekly semaglutide in adults with overweight or obesity.N Engl J Med2021;384:989-1002

[63] Davies M,Jeppesen OK.STEP 2 Study GroupSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet2021;397:971-84

[64] Rubino DM,Khalid U.STEP 8 InvestigatorsEffect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial.JAMA2022;327:138-50 PMCID:PMC8753508

[65] Lucas E,Tchang B.Pharmacologic management of weight regain following bariatric surgery.Front Endocrinol2022;13:1043595 PMCID:PMC9868802

[66] Aroda VR,Bardtrum L.Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.Lancet2023;402:693-704

[67] Knop FK,do Vale RD.OASIS 1 InvestigatorsOral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2023;402:705-19

[68] Garvey WT,Jastreboff AM.SURMOUNT-2 investigatorsTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2023;402:613-26

[69] Lee PC,Asokkumar R.Current treatment landscape for obesity in Singapore.Singapore Med J2023;64:172-81 PMCID:PMC10071854

[70] Frias JP,Erichsen L.Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet2023;402:720-30

[71] Rosenstock J,Jastreboff AM.Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet2023;402:529-44

[72] Jastreboff AM,Frías JP.Retatrutide Phase 2 Obesity Trial InvestigatorsTriple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial.N Engl J Med2023;389:514-26

[73] Shah A,Pierini E.Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery.Diabetes Obes Metab2018;20:1018-23 PMCID:PMC5847464

[74] Kim YG,Oh TJ,Park KS.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Diabetologia2013;56:696-708

[75] Kim YG,Oh TJ,Cho YM.Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.Diabetes Obes Metab2014;16:900-9

[76] Kashyap SR,Aminian A,Le Roux C.Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: a pilot study.Obes Sci Pract2020;6:255-63 PMCID:PMC7278903

[77] Abdul-Ghani MA.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.J Intern Med2014;276:352-63 PMCID:PMC5785085

[78] Lee PC,Goh SY.Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms.Obes Rev2018;19:1630-41

[79] Brown E,Cuthbertson DJ.SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.Lancet2021;398:262-76

[80] Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.Lancet2022;400:1788-801

[81] Cahn A,Dardano A.New forms of insulin and insulin therapies for the treatment of type 2 diabetes.Lancet Diabetes Endocrinol2015;3:638-52

[82] Ardestani A,Tavakkoli A.Insulin cessation and diabetes remission after bariatric surgery in adults with insulin-treated type 2 diabetes.Diabetes Care2015;38:659-64

[83] Aminian A,Arterburn DE.Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity.JAMA2019;322:1271-82 PMCID:PMC6724187

[84] Sjöström L,Jacobson P.Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.JAMA2014;311:2297-304

[85] Coleman KJ,Johnson E.Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery.Diabetes Care2016;39:1400-7 PMCID:PMC4955928

[86] Tschöp M,Ahrén B.Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.Diabetologia2023;66:1796-808 PMCID:PMC10474213